Vinkovci

Researchers are evaluating whether the medicine BI 764198 can help adults and adolescents with specific kidney diseases, including secondary focal segmental glomerulosclerosis, treatment-resistant primary minimal change disease, Alport Syndrome, and treatment-resistant primary membranous nephropathy. This Phase II study aims to assess the safety, tolerability, and effectiveness of BI 764198 compared to a placebo in these proteinuric kidney diseases. Participants are randomly assigned to one of two groups: one group takes BI 764198 tablets once daily, while the other takes placebo tablets that look like the medicine but contain no active drug. All participants continue their usual kidney disease treatments during the 20-week treatment period. After treatment, there is a follow-up period, and overall, participants are involved in the study for about seven months. During the study, participants visit the study site six times and have three phone calls with the study team. Doctors regularly collect urine and blood samples to monitor protein levels and kidney function. Researchers compare these results between the two groups to determine if BI 764198 affects kidney disease markers. Participants' health and any side effects are also closely monitored throughout the study.